GSK bets $1.3B on Mersana’s preclinical ADC and chance to expand portfolio beyond Blenrep

GSK has paid out $100 million cash to Mersana Therapeutics for the potential to add a second antibody-drug conjugate (ADC) to its portfolio, which currently consists of approved multiple myeloma drug Blenrep. The new deal encompasses XMT-2056, Mersana’s preclinical ADC asset aimed at treating a range of HER-2 cancers.